Validation pour Ingenuity407

vers la météo de la validation par utilisateur

Ingenuity407

precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 71 - PMID ?

Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant SP with a homozygous knockout of SP NODE .

Non annotée
Je ne sais pas
Je n'ai pas trouvé d'analyse satisfaisante

Commentaires :

Analyse 0

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 1

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 2

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 3

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 4

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 5

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 6

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 7

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 8

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 9

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 10

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 11

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |               |                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 12

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 13

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |               |                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 14

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 15

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 16

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 17

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 18

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 19

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 20

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 21

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 22

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 23

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 24

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 25

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 26

             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 27

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 28

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 29

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 30

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 31

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 32

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 33

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 34

             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                                           |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 35

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 36

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 37

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 38

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 39

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 40

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 41

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 42

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 43

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 44

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 45

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 46

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 47

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 48

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 49

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 50

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 51

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 52

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 53

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 54

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 55

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 56

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 57

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 58

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 59

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 60

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 61

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 62

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 63

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 64

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 65

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 66

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 67

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |               |                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 68

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 69

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 70

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 71

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             +----------------------------------APPOS----------------------------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 72

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 73

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             +----------------------------------APPOS----------------------------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 74

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 75

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 76

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 77

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 78

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 79

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 80

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 81

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 82

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 83

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 84

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 85

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 86

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 87

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 88

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 89

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 90

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 91

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 92

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 93

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 94

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 95

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 96

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 97

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 98

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 99

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 100

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 101

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 102

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 103

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 104

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 105

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 106

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 107

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 108

                                                                                                                      +------------------------COMP:N-N(with)-----------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 109

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 110

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 111

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 112

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 113

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 114

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 115

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 116

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 117

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 118

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 119

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 120

                                                                                                                      +------------------------COMP:N-N(with)-----------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 121

                                                                                                                      +------------------------COMP:N-N(with)-----------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 122

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 123

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 124

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 125

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 126

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 127

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 128

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 129

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 130

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 131

                                                                                                                      +------------------------COMP:N-N(with)-----------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 132

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 133

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 134

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 135

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 136

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 137

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 138

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 139

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 140

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 141

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 142

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 143

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 144

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 145

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 146

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 147

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 148

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 149

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 150

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
                                                                                                                                  +------------------COMP:N-N(with)-----------------+                  |     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                                           |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 151

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 152

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 153

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 154

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 155

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 156

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
                                                                                                                                  +------------------COMP:N-N(with)-----------------+                  |     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                                           |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 157

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 158

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 159

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 160

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 161

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 162

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 163

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 164

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 165

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 166

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 167

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 168

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 169

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 170

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 171

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 172

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 173

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 174

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 175

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 176

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 177

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 178

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 179

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 180

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 181

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 182

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 183

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 184

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 185

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 186

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 187

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 188

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 189

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 190

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 191

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 192

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 193

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 194

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 195

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 196

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 197

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 198

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 199

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 200

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 201

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 202

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |               |                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 203

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 204

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 205

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 206

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 207

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 208

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 209

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 210

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 211

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 212

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 213

             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 214

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 215

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 216

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 217

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 218

             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 219

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 220

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 221

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 222

             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                                           |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 223

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 224

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 225

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 226

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 227

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 228

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 229

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 230

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 231

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 232

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 233

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 234

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 235

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 236

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 237

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 238

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 239

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 240

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 241

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 242

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 243

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 244

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 245

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 246

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 247

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 248

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 249

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 250

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 251

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 252

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 253

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 254

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 255

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 256

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 257

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 258

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 259

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 260

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 261

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 262

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 263

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 264

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 265

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 266

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 267

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 268

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 269

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 270

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 271

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 272

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |               +--------------------------APPOS--------------------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 273

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 274

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 275

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 276

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 277

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 278

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 279

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 280

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 281

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 282

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 283

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 284

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 285

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 286

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 287

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 288

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 289

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 290

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 291

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 292

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 293

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 294

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 295

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 296

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 297

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 298

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 299

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 300

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 301

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 302

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 303

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 304

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 305

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 306

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 307

                                                                                                                                  +------------------COMP:N-N(with)-----------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 308

                                                                                                                      +------------------------COMP:N-N(with)-----------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 309

                                                                                                                                  +------------------COMP:N-N(with)-----------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 310

                                                                                                                      +------------------------COMP:N-N(with)-----------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 311

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 312

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 313

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 314

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 315

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 316

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 317

                                                                                                                      +------------------------COMP:N-N(with)-----------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 318

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 319

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 320

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 321

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 322

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 323

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 324

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 325

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 326

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 327

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 328

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 329

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 330

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 331

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 332

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 333

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 334

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 335

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 336

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 337

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 338

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
                                                                                                                                  +------------------COMP:N-N(with)-----------------+                  |     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 339

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 340

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 341

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
                                                                                                                                  +------------------COMP:N-N(with)-----------------+                  |     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 342

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 343

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 344

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 345

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 346

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 347

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 348

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 349

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
                                                                                                                                  +------------------COMP:N-N(with)-----------------+                  |     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 350

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 351

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 352

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 353

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 354

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 355

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 356

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 357

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 358

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 359

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 360

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 361

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 362

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 363

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 364

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 365

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 366

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 367

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 368

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 369

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 370

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 371

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 372

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 373

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 374

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 375

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 376

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 377

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 378

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 379

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 380

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 381

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 382

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 383

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

Analyse 384

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 385

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 386

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 387

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 388

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 389

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 390

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 391

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 392

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 393

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 394

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 395

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 396

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 397

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 398

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 399

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 400

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 401

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 402

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 403

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 404

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 405

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 406

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 407

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

Analyse 408

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)